BioWorld

May 8, 2009

Vanda Shares Surge 626% on FDA Approval of Fanapt

Shares in Vanda Pharmaceuticals Inc. rocketed into the stratosphere Thursday on news of the FDA's surprising approval of the company's antipsychotic Fanapt. (BioWorld Today) Read More

HHS Officials Provide More Details on HHS FY 2010 Budget

Candidate Culprit for Multiple Sclerosis Gray Matter Damage

Zenobia Takes Up Arms Against Parkinson's, Other CNS Diseases

Licensing Deal Gives Pharma Firm Majority of Cornerstone

Financings Roundup

Other News To Note

Clinic Roundup

Earnings Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 24, 2025.

Moderna expands mRNA tech to latent viruses, cancer, rare disease

BioWorld

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

Otsuka licenses Harbour’s bispecific T-cell engager for $670M

BioWorld

Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....

Revmed goes global with $2B in capital for RAS(ON) inhibitors

BioWorld

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...